Yttrium 90-labelled edotreotide

N/A

Report date: 2025/11/20 13:28:34
NME

Base Information

Drug NameYttrium 90-labelled edotreotide
Drug Alias Name钇[90Y]-伊索曲肽Y-90 SMT-48790Y-SMT 487钇[90Y]-依多曲肽Yttrium 90 labelled endotreotide +[13] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIonising radiation emittersSomatostatin receptor 2 binders
TargetsSomatostatin receptor 2
Therapy Area/IndicationsSkin MelanomaCNS Embryonal TumorSolid tumours +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItaly
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgThe University Of Iowa
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthNational Cancer Institute
Inactive CompaniesEuropean Institute Of OncologyThe University Of IowaNovartis Pharma Ag +[4] 
Active IndicationsCarcinoid TumorNeuroendocrine TumorsNeuroblastoma +[4] 
Inactive IndicationsSkin MelanomaCNS Embryonal TumorSolid tumours +[11] 

Other Information

ATC CodeN/A
Related LinksN/A